- Market Research
- Stocks Research
- ETF Research
- Mutual Funds Research
- Options Research
- Bonds & Fixed Income Research
Stock Research
Stock Quotes & Research Tools
View our stock quotes and sample our research offering.
Try our powerful stock tools to help compare investments and get ideas.
Find out about our industry leading research providers.
| Last Price | Today's Change | Today's Volume |
|---|---|---|
| $24.54 | +0.28 (1.15%) | 214,462Below Average |
Details | |
|---|---|
| Today's Open | $24.61 |
| Previous Close | $24.26 |
| Day's Range | $23.91 - $24.81 |
| 52 Week range | $8.20 - $24.88 |
| Beta | 1.80 |
| Avg. Volume (10 Day) | 3,315,854 |
| Put/Call Ratio (1 Day) | 2.0 |
| Put/Call Ratio (30 Day) | 1.8 |
Dividends | |
|---|---|
NRIX does not currently pay a dividend. |
Shares | |
|---|---|
| Market Capitalization (Small Cap) | $2.5B |
| Shares Outstanding | 103.4M |
| Shares Held By Institutions | 108% |
- Form 4 Nurix Therapeutics, Inc. For: Jun 25 Filed by: Hansen Gwenn
- Form 4 Nurix Therapeutics, Inc. For: Jun 25 Filed by: Ring Christine
- Form 144 Nurix Therapeutics, Inc. Filed by: Ring Christine
- Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
- Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
- Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
- Form 4 Nurix Therapeutics, Inc. For: Jun 25 Filed by: Hansen Gwenn
- Form 4 Nurix Therapeutics, Inc. For: Jun 25 Filed by: Ring Christine
- Form 144 Nurix Therapeutics, Inc. Filed by: Ring Christine
View the rationale behind our Schwab Equity Rating with details on what factors and components contribute to the overall rating.
Qualitative analysis on Morningstar’s global equity coverage. Analyst commentary, star ratings and economic moat evaluations.
This report contains the Argus rating and qualitative assessment of a stock's investment potential.
CFRA's Stock Reports contain equity analysis covering 5,000 publicly traded companies. The reports provide CFRA's ranking and qualitative opinion, financial statistics, and up to 10 years of summary balance sheet and income statement data.
Detailed financials and consensus ratings from Refinitiv.
Manage market risk with quantitative technical analysis models from Market Edge.
Quotes are delayed by at least 15 minutes. Before trading, please check a real-time quote for current information.
Important Disclosures
Schwab Equity Ratings and other materials are for informational purposes only and is not an offer to sell or the solicitation of an offer to buy. Schwab Equity Ratings and the general buy/sell/hold guidance are not personal recommendations for any particular investor or client and do not take into account the financial, investment or other objectives or needs of, and may not be suitable for any particular investor or client. Before buying, investors and clients should consider whether the investment is suitable. Investors and clients should consider Schwab Equity Ratings as only a single factor in making their investment decision while taking into account the current market environment.
Schwab Equity Ratings utilize third-party data in the forming of a rating. Data is obtained from what are considered reliable sources; however, its accuracy, completeness or reliability cannot be guaranteed. Schwab Equity Ratings are generally updated weekly, so you should review and consider any recent market or company news before taking any action. Stocks may go down as well as up and investors (including clients) may lose money, including their original investment. Past performance is no indication of future results and returns are not guaranteed. For individualized advice, please contact Schwab at 1 (877) 284-9817. Note: An asterisk (*) next to a Schwab Equity Rating means that a potentially significant even has been announced for an A or B rated stock, Although Schwab generally does not monitor C, D, and F rated stocks for current news, from time to time, asterisks may appear on a particular stock due to certain circumstances (e.g. the downgrade of a stock from a B to C rating).
The news sources used on Schwab.com come from independent third parties. Schwab is not affiliated with any of the news content providers. Schwab is not responsible for the content, and does not write or control which particular article appears on its website. The securities markets (1) reserve all rights to the market data that they make available; (2) do not guarantee that data; and (3) shall not be liable for any loss due either to their negligence or to any cause beyond their reasonable control.